Table 5 Antiviral treatment of immunosuppressed patients with influenza infections
All types (n = 111) | Malignancies (n = 71) | HSCT (n = 26) | Autoimmune disorders (n = 10) | |
|---|---|---|---|---|
Antiviral treatment (%) | 104/111 (93.7) | 65/71 (91.5) | 25/26 (96.2) | 10/10 (100.0) |
No antiviral treatment (%) | 7/111 (6.3) | 6/71 (8.5) | 1/26 (3.8) | 0/10 (0.0) |
Antiviral treatment within 48 h (%) | 93/111 (83.8) | 60/71 (84.5) | 20/26 (76.9) | 9/10 (90.0) |
Antiviral treatment after 48 h (%) | 11/111 (9.9) | 5/71 (7.0) | 5/26 (19.2) | 1/10 (10.0) |
Oseltamivir (%) | 79/104 (76.0) | 52/65 (80.0) | 15/25 (60.0) | 9/10 (90.0) |
Peramivir (%) | 9/104 (8.6) | 7/65 (10.8) | 2/25 (8.0) | 0/10 (0.0) |
Combination of oseltamivir and peramivir (%) | 16/104 (15.4) | 6/65 (9.2) | 8/25 (32.0) | 1/10 (10.0) |
Standard dose of neuraminidase inhibitors (%) | 93/104 (89.4) | 59/65 (90.8) | 21/25 (84.0) | 9/10 (90.0) |
Double dose of neuraminidase inhibitors (%) | 11/104 (10.6) | 6/65 (9.2) | 4/25 (16.0) | 1/10 (10.0) |